Affiliation:
1. Institute of Medical Science, Department of Immunology and Surgery, University of Toronto, C/O 429 Drewry Avenue, Toronto, ON M2R 2K6, Canada
Abstract
The field of clinical oncology has been revolutionized over the past decade with the introduction of many new immunotherapies the existence of which have depended to a large extent on experimentation with both in vitro analysis and the use of various animal models, including gene-modified mice. The discussion below will review my own laboratory’s studies, along with those of others in the field, on cancer immunotherapy. Our own studies have predominantly dwelt on two models of malignancy, namely a solid tumor model (breast cancer) and lymphoma. The data from our own laboratory, and that of other scientists, highlights the novel information so obtained, and the evidence that application of such information has already had an impact on immunotherapy of human oncologic diseases
Funder
Canadian Institutes of Health Research
Breast Cancer research Foundation
Reference107 articles.
1. Chackalamannil, S., Rotella, D., and Ward, S. (2017). Cancer Immunotherapy—An Emerging Field That Bridges Oncology and Immunology Research, Elsevier. Comprehensive Medicinal Chemistry III.
2. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice;Ansari;J. Exp. Med.,2003
3. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4;Tivol;Immunity,1995
4. Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells;Chambers;Immunity,1997
5. Zhang, J., Zhang, M., Jiang, W., Wang, L., Fu, Z., Li, D., and Pang, D. (2009). B7-H4 gene polymorphisms are associated with sporadic breast cancer in a Chinese Han population. BMC Cancer, 9.